Alnylam Pharmaceuticals EBIT 2010-2025 | ALNY

Alnylam Pharmaceuticals EBIT for the quarter ending March 31, 2025 was $0.018B, a 141.62% decline year-over-year.

  • Alnylam Pharmaceuticals 2024 EBIT was -0.177B, a 37.31% decline from 2023.
  • Alnylam Pharmaceuticals 2023 EBIT was -0.282B, a 64.06% decline from 2022.
  • Alnylam Pharmaceuticals 2022 EBIT was -0.785B, a 10.78% increase from 2021.

EBIT can be defined as earnings before interest and taxes.

Alnylam Pharmaceuticals EBIT 2010-2025 | ALNY

  • Alnylam Pharmaceuticals 2024 EBIT was -0.177B, a 37.31% decline from 2023.
  • Alnylam Pharmaceuticals 2023 EBIT was -0.282B, a 64.06% decline from 2022.
  • Alnylam Pharmaceuticals 2022 EBIT was -0.785B, a 10.78% increase from 2021.

EBIT can be defined as earnings before interest and taxes.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$218.6B
Amgen (AMGN)$164.4B
Gilead Sciences (GILD)$137B
Vertex Pharmaceuticals (VRTX)$120.7B
Bristol Myers Squibb (BMY)$97.7B
CSL (CSLLY)$84.2B
GSK (GSK)$75.8B
Regeneron Pharmaceuticals (REGN)$60.6B
Argenex SE (ARGX)$35B
BioNTech SE (BNTX)$26.8B
Royalty Pharma (RPRX)$20.3B
Insmed (INSM)$19.5B
Biogen (BIIB)$18.7B
Illumina (ILMN)$16.2B
Genmab (GMAB)$14B
Genmab (GNMSF)$13.8B
Incyte (INCY)$13.3B
Moderna (MRNA)$12.7B
Exelixis (EXEL)$12.1B
BioMarin Pharmaceutical (BMRN)$11.4B
QIAGEN (QGEN)$11B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.1B
Exact Sciences (EXAS)$9.4B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$8.3B
Legend Biotech (LEGN)$8.1B
Roivant Sciences (ROIV)$7.8B
Revolution Medicines (RVMD)$7.1B